CLNN Stock Forecast & Price Target

Clene Inc. has demonstrated a durable and statistically significant survival advantage in its clinical analyses, confirming the efficacy of its lead therapeutic candidate, CNM-Au8, particularly in treating neurodegenerative diseases like amyotrophic lateral sclerosis. The reported biomarker improvements, notably reductions in neurofilament light (NfL) levels and GFAP, provide compelling evidence of the therapy’s disease-modifying potential, aligning with FDA accelerated approval pathways. Furthermore, management's confidence in their current financial position, coupled with positive trial outcomes and a strong safety profile, positions Clene favorably for future financing opportunities and enhanced program de-risking.

Clene Inc reported a net loss of $8.8 million in the third quarter of 2025, reflecting a decline in share value from $1.22 per share to $0.85 per share year-over-year, primarily due to decreased research and development and general and administrative expenses, although partially offset by higher other expenses. Despite some positive indicators from FDA-recommended analyses regarding biomarker reductions in clinical trials, the Phase 2 trials for HEALEY and RESCUE missed their primary endpoints, casting doubt on the efficacy of the company's therapeutic candidates. Additionally, the ongoing challenges related to the brain's energy demands and the implications for ATP synthesis may further complicate the development of effective treatments for neurodegenerative diseases, contributing to a more negative outlook on Clene's stock performance.